
Academic Journal
Q1CNS Drugs
About CNS Drugs
CNS Drugs is a scholarly journal published by its listed publisher. SCImago 2025 lists it in Q1, with an SJR of 2.161 and H-index of 140.
Coverage: 1994-2026. Research categories: Neurology (clinical) (Q1); Pharmacology (medical) (Q1); Psychiatry and Mental Health (Q1).
Verified field sources
- Journal Impact Factor: 7.0 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
- Impact Factor year: 2025 — Official source; checked 2026-10-03. Journal metric year and editorial leadership as listed on the Springer Nature journal homepage.
Source-backed journal facts
Topics in published research
Schizophrenia research and treatment; Epilepsy research and treatment; Treatment of Major Depression; Pharmacological Effects and Toxicity Studies; Bipolar Disorder and Treatment; Neurotransmitter Receptor Influence on Behavior.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Reported open-access list prices
5,090.00 USD; 3,990.00 EUR; 3,190.00 GBP
APC list prices reported by OpenAlex, which obtains this information from DOAJ. Confirm current charges, taxes, waivers and eligibility with the publisher; this is not a fee quotation.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Cognitive Effects of Cenobamate as Compared to Perampanel: A Cross-Sectional Multicentre Study in 600 Patients
Juri-Alexander Witt, Judit Catalán-Aguilar, Elisa Schütz, Randi von Wrede et al.
2026-10-02 · DOI: 10.1007/s40263-026-01340-6Eculizumab and Ravulizumab During Pregnancy in Neuromyelitis Optica Spectrum Disorder and Myasthenia Gravis: Balancing Maternal Disease Control and Fetal Safety
Eva Dhupia, Jennifer A. McCombe, Sean J. Pittock, Nabeela Nathoo et al.
2026-09-30 · DOI: 10.1007/s40263-026-01339-zRozanolixizumab: A Review in AChR or MuSK Autoantibody-Positive Generalised Myasthenia Gravis
Aisling McGuigan, Hannah A. Blair
2026-09-30 · DOI: 10.1007/s40263-026-01335-3Approved Medications for Substance Use Disorders: An Umbrella Review of Systematic Reviews and Completed Phase 3 Randomized Controlled Trials
Itai Danovitch, Kyla Truman, Haze Brown, Macie Miller et al.
2026-09-23 · DOI: 10.1007/s40263-026-01334-4From Proof of Principle to Therapeutic Discipline: Strategies to Improve the Benefit/Risk Profile of Amyloid-Targeting Treatments for Alzheimer’s Disease
Robert Perneczky, Frank Jessen, Timo Grimmer, Johannes Levin et al.
2026-09-15 · DOI: 10.1007/s40263-026-01333-5Bistromathics in Epilepsy and the Relativity of Numbers
Emilio Russo, Roberta Roberti, Eugen Trinka
2026-09-11 · DOI: 10.1007/s40263-026-01336-2Cognitive Side Effects of Antiseizure Medications in Adults with Epilepsy: An Update with a Focus on New Therapeutic Agents
Marco Mula
2026-09-09 · DOI: 10.1007/s40263-026-01331-7Correction: Efficacy and Safety of an Early Aggressive Lipid‑Lowering Strategy Using Triple Therapy After Mechanical Thrombectomy
Ho Geol Woo, Jaeyu Park, Tae-Jin Song, Mi-Yeon Eun et al.
2026-09-04 · DOI: 10.1007/s40263-026-01332-6Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms
Alana King, Morgan Hardy, Taeho Greg Rhee, Samuel T. Wilkinson et al.
2026-08-26 · DOI: 10.1007/s40263-026-01330-8Opioid Add-On Combination Therapy for Cancer Pain: Pharmacological Rationale, Clinical Evidence, and Future Directions
Sebastiano Mercadante
2026-10 · DOI: 10.1007/s40263-026-01329-1Candidate Clinico-Demographic Predictors or Moderators of Efficacy and Tolerability of Pharmacological Treatment in Attention-Deficit/Hyperactivity Disorder (ADHD): An Analysis of the MED-ADHD Repository of Randomised Controlled Trials
Sulagna Roy, Guilherme Fusetto Veronesi, Sara Mannarini, Daniele Pirolo et al.
2026-08-13 · DOI: 10.1007/s40263-026-01323-7Efficacy and Safety of Psychedelic Microdosing on Psychological Outcomes in Healthy Adults: A Systematic Review and Meta-analysis
Shakila Meshkat, Marco Leung, Sarina Meshkat, Qiaowei Lin et al.
2026-10 · DOI: 10.1007/s40263-026-01325-5Heterogeneity in Teriflunomide Treatment Arms: A Systematic Review and Meta‑Regression of Randomised Multiple Sclerosis Trials
Francesca Bovis, Alessio Signori, Mirko Capanna, Noemi Montobbio et al.
2026-10 · DOI: 10.1007/s40263-026-01328-2Impact of Psilocybin on Motor Function in Healthy Participants: A Phase 1, Randomised, Triple-Blind, Dose-Finding Study
Chiranth Bhagavan, Olivia Carter, Glenn Nielsen, David Berlowitz et al.
2026-08-07 · DOI: 10.1007/s40263-026-01326-4Sigma-1 Receptor Ligand Blarcamesine (ANAVEX 2-73) for Alzheimer’s Disease: A Systematic Review
Sirikalaya Brimson, Premrutai Thitilertdecha, Kishoree Krishna Kumaree, James Michael Brimson et al.
2026-09 · DOI: 10.1007/s40263-026-01327-3Efficacy and Safety of an Early Aggressive Lipid-Lowering Strategy Using Triple Therapy After Mechanical Thrombectomy
Ho Geol Woo, Jaeyu Park, Tae-Jin Song, Mi-Yeon Eun et al.
2026-08-03 · DOI: 10.1007/s40263-026-01321-9PDE10A Inhibition in Schizophrenia: A Randomised, Placebo-Controlled Phase 2 Study of Alofropodect (CPL’36) in Patients Experiencing Acute Schizophrenia
Maciej Wieczorek, Napoleon Waszkiewicz, Ewa Gromniak-Haniecka, János M. Réthelyi et al.
2026-09 · DOI: 10.1007/s40263-026-01317-5Adjunctive Pharmacotherapy for Major Depressive Disorder with Anxiety Symptoms: from Monoamines to Recent Clinical Evidence
Roger S. McIntyre, Masaki Kato, Michael E. Thase, François Therrien et al.
2026-09 · DOI: 10.1007/s40263-026-01315-7Comparative Bioavailability of Trimodal (CTx-1301) Versus Bimodal Dexmethylphenidate Modified-Release Formulations in Adults with Attention-Deficit/Hyperactivity Disorder: A Randomized, Single-Dose, Crossover Study
Arthur B. Straughn, Raul Silva, Michael J. Cattaneo, Kelly Koehn et al.
2026-10 · DOI: 10.1007/s40263-026-01319-3Recent Locoregional CAR T-Cell Trials for the Treatment of Recurrent Glioblastoma: Implications for Neuro-Oncology Practice
Manina Maja Etter, Kevin Akeret, Raphael Guzman, Luigi Mariani et al.
2026-10 · DOI: 10.1007/s40263-026-01322-8Reviews
Community Reviews
Version History
September 25, 2026 at 7:09 am
September 25, 2026